Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.

Join us as we host Assembly Bio for an in-depth discussion on recurrent genital herpes (RGH). This talk will provide an overview of RGH epidemiology, real-world disease burden, and impact on affected individuals. We will review the current treatment landscape and patient journey, highlight the state of clinical science, and discuss the rationale for advancing long-acting therapeutic approaches.

The presentation will introduce Assembly Bio’s investigational candidates, ABI-5366 and ABI-1179, including their targets and differentiation relative to standard therapies such as valacyclovir. Finally, we will summarize Phase 1 findings and outline plans for Phase 2 development.

Register for this talk here: https://us06web.zoom.us/meeting/register/y3niff9HTaWUS6CgIvedig